Roactemra 162 mg solution for injection in pre-filled syringe    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
41Giant cell arteritis1

41. Giant cell arteritis    [ 108 clinical trials,   111 drugs,   (DrugBank: 32 drugs),   33 drug target genes,   121 drug target pathways]
Searched query = "Giant cell arteritis", "Temporal arteritis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 108 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2016-002716-41-FR
(EUCTR)
24/05/201704/04/2017A STUDY TO EVALUATE LONG TERM SAFETY OF TOCILIZUMAB IN PATIENTS WITH GIANT CELL ARTERITIS WHO HAVE COMPLETED WA28119 CORE STUDY IN FRANCEAN EXTENSION STUDY TO EVALUATE LONG TERM SAFETY OF SUBCUTANEOUS TOCILIZUMAB IN PATIENTS WITH GIANT CELL ARTERITIS WHO HAVE COMPLETED WA28119 CORE STUDY IN FRANCE, AND SUBSEQUENTLY HAVING FLARE OR PERSISTING DISEASE ACTIVITY Giant cell arteritis (GCA)
MedDRA version: 19.1;Level: LLT;Classification code 10018250;Term: Giant cell arteritis;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: RoActemra 162 mg solution for injection in pre-filled syringe
INN or Proposed INN: tocilizumab
Other descriptive name: TOCILIZUMAB
ROCHE SASNULLNot RecruitingFemale: yes
Male: yes
10Phase 3France